Barclays Raises Hims & Hers (HIMS) Price Target to $39 on GLP-1 Momentum

Barclays reiterated its bullish rating on Hims & Hers Health (NYSE: HIMS) and raised its price target from $29 to $39, citing building momentum in the company's GLP-1 product line and an approaching FDA decision on peptides expected in July. Shares of HIMS gained 11.23% on Thursday, June 18, 2026, closing at $35.47.

What Changed

• Price target raised: Barclays lifted its HIMS target to $39, up from $29, representing a $10 increase.
• GLP-1 momentum cited: The upgrade note pointed to Hims & Hers' pivot to branded GLP-1 products as a driver of subscriber and engagement growth, according to Barclays.
• July FDA catalyst: Analysts flagged an upcoming FDA ruling on peptides, expected in July, as a near-term event with material implications for the company's product portfolio.
• Novo Nordisk partnership: Separate analyst commentary referenced a Novo Nordisk partnership and cross-selling opportunities as additional factors supporting the bull case, according to Seeking Alpha.
• Longevity market backdrop: TD Cowen analysts estimated the total addressable market for longevity healthcare exceeds $250 billion, a broader sector dynamic that analysts have linked to companies including Hims & Hers.

Why It Matters

The Barclays target revision arrives as Hims & Hers navigates a strategic shift away from compounded GLP-1 formulations toward branded products, following the resolution of earlier legal and regulatory uncertainties around that transition. According to Seeking Alpha coverage, the move to branded GLP-1 offerings has already driven engagement and subscriber growth, providing a commercial foundation ahead of the July FDA peptide decision.

The July FDA ruling on peptides represents a discrete binary event for the company's product roadmap. Analysts at Barclays characterized the combination of GLP-1 momentum and the pending regulatory decision as sufficient to justify the higher target, with HIMS shares now trading above $30 for the first time in recent sessions ahead of that ruling.

Wall Street View

Barclays' revised $39 target reflects the firm's view that the risk profile around Hims & Hers has improved following the legal resolution tied to its GLP-1 pivot. The broader analyst community remains split: the consensus as of June 1, 2026 stood at 2 Strong Buy, 8 Buy, and 13 Hold ratings, with no Sell or Strong Sell recommendations, unchanged from the prior month. The Barclays action is notable as one of the more aggressive target increases in the recent coverage cycle.

Investor Takeaway

Barclays' move to a $39 price target, up from $29, gives HIMS a concrete near-term benchmark as the company approaches the July FDA peptide decision. With shares closing at $35.47 following Thursday's 11.23% gain, the stock is trading within that revised target range, meaning the next material catalyst is likely the FDA ruling itself rather than further analyst re-rating.